If you have a question for our guest, host or DRG please submit it here.
Impact of COVID-19 on the development of CAR T-cell therapies
Guest: Dana Gheorghe, Ph.D, Associate Director, Oncology
In this episode of Conversations in healthcare, Mike Ward, Global Head of Thought Leadership talks to Dana Gheorghe, Ph.D, Associate Director, Oncology, about the impact COVID-19 is having on treatment for already available CAR T-cell therapies as well as those being developed. Dana gives us the lay of the land in an area where there is scarcity of information that is frequently changing. Dana covers how patients are being prioritised according to risk and need at this time and the challenges of getting high risk patient profiles much needed treatments. She also discusses the various country and region-specific conditions that are being put in place to allow treatment and trials to continue, however, many existing trials and read outs have been delayed despite and new trials completely suspended. Watch the full episode to understand the full impact.
About our Guest
Dana Gheorghe, Ph.D, Associate Director, Oncology
Dana manages a team of analysts whose market research spans several oncology indications. She has extensive expertise forecasting drug markets for a wide range of oncology indications, including breast cancer, non-Hodgkin’s and Hodgkin’s lymphoma. Prior to joining DRG, she worked as a postdoctoral fellow at Imperial College London and at the Marie Curie Research Institute. She obtained her doctorate from the University of Sheffield.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.